The annual Controlling Cancer Summit is an international academic event with plenty of opportunity for networking and debate.
In an informal setting, this meeting will bring you up to date with current research and thinking regarding screening, prevention and treatment in this ever-growing field. Presenting at this event, we will have a variety of clinicians, academics and members of the pharmaceutical industry; we encourage presentations from the wide spectrum of cancer research, development and healthcare professionals.
Deadlines
- The Deadline for abstract submissions for oral presentation is 10th February 2016
- The early registration deadline is 20th March 2016
- The Deadline for poster submission is 3rd May 2016
Who Should Attend: This innovative and stimulating event is aimed at those working in research and development of drugs, industry partners, academia, biotechnology, diagnostic, clinicians and postgraduate students.
THIS EVENT HAS NOW PASSED
TO SEE A LIST OF OUR FUTURE EVENTS GO TO
Talks Include
| Talk | Speaker | Affiliation | Country |
|---|---|---|---|
| Dendritic cell derived exosomes for cancer therapy | Associate Professor Susanne Gabrielsson | Karolinska Institutet | Sweden |
| New therapeutic approaches and repurposed drugs for targeting of glioma stem cells and treatment of glioblastoma | Professor Chaya Brodie | Hermelin Brain Tumor Center | United States |
| The antitumor activity of cannabinoids in colorectal cancer | Dr David Meiri | Technion-Israel Institute of Technology | Israel |
| The stress protein TP53INP1 plays a tumor suppressive role by regulating metabolic homeostasis | Dr. Alice Carrier | Cancer Research Center of Marseille (CRCM) | France |
| NQO1, GSTM1, and GSTT1 genetic polymorphisms and the risk of developing cancer among Filipinos | Dr Pia Marie Albano | Research Center for the Natural and Applied Sciences | Philippines |
| DNA damage repair and p53 gene in platinum-drug resistance | Dr Jing Jie Yu | Mary Babb Randolph Cancer Center | United States |
| Using chemical and biological data for targeted compound selection and biomarker discovery in cancer and beyond | Dr Andreas Bender | University of Cambridge | United Kingdom |
| DNA repair gene polymorphisms as risk factors and chemotherapy response predictors for lung adenocarcinoma in Serbia | Ivana Boljevic | Laboratory for Molecular Genetics,Institute for Oncology and Radiology of Serbia | Serbia |
| CYP3A variation, hormone levels, breast cancer risk and prognosis | Dr Olivia Fletcher | Genetic Epidemiology The Institute of Cancer Research | United Kingdom |
| Omics biomarkers and their implication in cancer control | Dr Mukesh Verma | National Institutes of Health (NIH) | United States |
| p53 regulates miRNA-AGO2 association to control miRNA-mediated post-transcriptional gene repression in cancer | Dr Leandro Castellano | Imperial College London | United Kingdom |
| Targeting non death domain-containing TNFR family members for cancer therapy: direct, carcinoma cell-specific death by CD40 signalling | Dr Nikolaos Georgopoulos | University of Huddersfield | United Kingdom |
| Non-Natural Nucleosides as Therapeutic Agents Against Glioblastoma | Dr Anthony J. Berdis | Cleveland State University | United States |
| Nucleosomics®- Revolutionising Cancer Diagnostics | Dr Mark Eccleston | VolitionRx | United Kingdom |
| Cancer resistance to photodynamic therapy | Dr. Marek Murias | Poznan University of Medical Sciences | Poland |
| IV Iron in Anemia of Oncology, Inflammation, and other disorders of Iron deficiency | Dr David Henry | University of Pennsylvania | United States |
| DNA methylation in epithelial-to-mesenchymal transition | Dr Bozena Smolkova | Slovak Academy of Sciences | Slovakia |
| Adoptive T cell Therapy for Cancer | Dr David Edward Gilham | The University of Manchester | United Kingdom |
| Crosstalk between cell death modalities as anticancer target | Dr Marc Diederich | Seoul National University | Korea |
| Targeted nanomedicines in cancer therapy | Dr Christine Dufes | University of Strathclyde | United Kingdom |
| Signalling therapy for cancer: from target proteins to target signalling networks | Dr Alexey Goltsov | University of Abertay Dundee | United Kingdom |
| Stem Cell based Therapies for Cancer: Mechanism and Translation into Clinics | Dr. Khalid Shah | Harvard Medical School | United States |
| DNA methylation in early detection and risk prediction of women specific cancers | Professor Martin Widschwendter | Institute for Women´s Health | United Kingdom |
| Cognitive impairment in patients with glioblastoma: single institution experience | Dr. Ana Misir Krpan | University Hospital Center Zagreb | Croatia |
| Precious metals for cancer treatment - a novel approach | Isolda Romero | University of Warwick | United Kingdom |
| Molecular factors associated with resistance to drugs targeting BRAF in malignant melanoma | Dr Suzanne Egyházi Brage | Department of Oncology-Pathology | Sweden |
| Responsive lanthanide complexes for imaging of key cell cycle regulators and inhibition of tumor cells | Dr. Gary Ka-Leung Wong | Hong Kong Baptist University | Hong Kong |
| Immunotherapy for cancer dormancy | Dr. Masoud H. Manjili | VCU School of Medicine | United States |
| RAD18 is involved in the resistance of glioblastoma cancer stem cells to the therapy. | Dr Chames Kermi | Genome Surveillance and Stability Laboratory, Institute of Human Genetics (IGH) | France |
| Recognition of LINE-1 derived DNA by the cGAS-STING pathway leads to inflammation in Fanconi Anemia | Dr. Jessica Guerra | CNRS | Montpellier, France |
| Adoptive T cell Therapy for Cancer | Dr.Gray Kueberuwa | University of Manchester | United Kingdom |
| TBC | Dr Kenneth J. Hsu | Kenneth Hsu Center of Cancer Studies | United Kingdom |
Advisory Board Members
| Member | Affiliation | Country |
|---|---|---|
| Dr Hendrik-Tobias Arkenau | Sarah Cannon Research Institute UK | United Kingdom |
| Professor Rui Amaral Mendes | Case Western Reserve University | United States |
| Professor Anthony Miller | University of Toronto | Canada |
| Dr Alenka Fokter | Celje General Hospital | Slovenia |
| Dr. Xiaoyan Jiang | BC Cancer Agency and University of British Columbia | Canada |
| Professor Shimon Slavin | The International Center for Cell Therapy & Cancer Immunotherapy (CTCI) | Israel |
The Controlling Cancer Summit 2016 has an open abstract session: Abstracts can be submitted on any subject related to cancer
CPD Credits
| Credits from The Institute of Biomedical Science (code) | Approved by the Royal Society of Biology for purposes of CPD | ||
|---|---|---|---|
| 18(MD028N16) | This event may be counted as 54 CPD credits |
Related Past Agendas
Related past events
